Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

44.1%

15 terminated/withdrawn out of 34 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

11 recruiting13 terminated

Enrollment Performance

Analytics

Phase 1

24(70.6%)

Early Phase 1

6(17.6%)

N/A

3(8.8%)

Phase 2

1(2.9%)

34Total

Phase 1(24)

Early Phase 1(6)

N/A(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (34)

Showing 20 of 34 trials

NCT05654779Phase 1Terminated

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT07399444Early Phase 1Not Yet Recruiting

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

Role: collaborator

NCT06197178Phase 1Terminated

A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)

Role: collaborator

NCT07331272Phase 1Recruiting

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Role: lead

NCT07100067Not ApplicableRecruiting

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

Role: lead

NCT07294625Early Phase 1Recruiting

A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT03758417Phase 2Terminated

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT07095075Early Phase 1Recruiting

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT07049081Phase 1Recruiting

A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT06295549Phase 1Terminated

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Role: collaborator

NCT07002112Phase 1Recruiting

The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Role: collaborator

NCT05376345Phase 1Terminated

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT06866080Early Phase 1Withdrawn

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT06869278Phase 1Recruiting

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Role: collaborator

NCT05292898Phase 1Terminated

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Role: collaborator

NCT05318963Phase 1Terminated

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Role: collaborator

NCT06313957Phase 1Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Role: collaborator

NCT06653556Early Phase 1Recruiting

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

Role: collaborator

NCT06395870Phase 1Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Role: collaborator

NCT06494371Phase 1Recruiting

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

Role: collaborator